Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity - PubMed (original) (raw)

. 2001 Feb 15;61(4):1247-9.

Affiliations

PMID: 11245412

Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity

C Nervi et al. Cancer Res. 2001.

Abstract

Remodeling of the chromatin template by inhibition of histone deacetylase (HDAC) activities represents a major goal for transcriptional therapy in neoplastic diseases. Recently, a number of specific and potent HDAC-inhibitors that modulate in vitro cell growth and differentiation have been developed. In this study we analyzed the effect of trichostatin A (TSA), a specific and potent HDAC-inhibitor, on mouse embryos developing in vivo. When administered i.p. to pregnant mice (at a concentration of 0.5-1 mg/kg) at postimplantation stages (embryonic day 8 to embryonic day 10), TSA was not toxic for the mother and did not cause any obvious malformation during somitogenesis or at later stages of development. Treated embryos were born at similar frequency and were indistinguishable from control animals, developed normally, and were fertile. Interestingly, embryos from TSA-treated mice killed during somitogenesis were modestly but consistently larger than control embryos and presented an increased (+2 to +6) number of somites. This correlated with an increased acetylation of histone H4, the number of somites expressing the myogenic factor Myf-5, and the expression of Notch, RARalpha2, and RARbeta2 mRNAs. These data indicate that the effects of TSA on transcription: (a) are not toxic for the mother; (b) transiently accelerated growth in mouse embryos without perturbing embryogenesis; and (c) do not result in teratogenesis, at least in rodents. Thus, TSA might represent a nontoxic and effective agent for the transcriptional therapy of neoplasia.

PubMed Disclaimer

Cited by

Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices.
Raviraj V, Fok S, Zhao J, Chien HY, Lyons JG, Thompson EW, Soon L. Raviraj V, et al. BMC Cell Biol. 2012 May 14;13:12. doi: 10.1186/1471-2121-13-12. BMC Cell Biol. 2012. PMID: 22583596 Free PMC article.
Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.
Chittur SV, Sangster-Guity N, McCormick PJ. Chittur SV, et al. BMC Genomics. 2008 Oct 29;9:507. doi: 10.1186/1471-2164-9-507. BMC Genomics. 2008. PMID: 18959802 Free PMC article.
Teratoma Growth Retardation by HDACi Treatment of the Tumor Embryonal Source.
Krasic J, Skara L, Ulamec M, Katusic Bojanac A, Dabelic S, Bulic-Jakus F, Jezek D, Sincic N. Krasic J, et al. Cancers (Basel). 2020 Nov 18;12(11):3416. doi: 10.3390/cancers12113416. Cancers (Basel). 2020. PMID: 33217978 Free PMC article.
Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases.
Iezzi S, Cossu G, Nervi C, Sartorelli V, Puri PL. Iezzi S, et al. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7757-62. doi: 10.1073/pnas.112218599. Proc Natl Acad Sci U S A. 2002. PMID: 12032356 Free PMC article.
CBP histone acetyltransferase activity is a critical component of memory consolidation.
Korzus E, Rosenfeld MG, Mayford M. Korzus E, et al. Neuron. 2004 Jun 24;42(6):961-72. doi: 10.1016/j.neuron.2004.06.002. Neuron. 2004. PMID: 15207240 Free PMC article.

Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity - PubMed (original) (raw)